These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16990759)

  • 1. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Renneville A; Quesnel B; Charpentier A; Terriou L; Crinquette A; Laï JL; Cossement C; Lionne-Huyghe P; Rose C; Bauters F; Preudhomme C
    Leukemia; 2006 Nov; 20(11):2067-70. PubMed ID: 16990759
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
    Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
    Steensma DP; Caudill JS; Pardanani A; McClure RF; Lasho TL; Tefferi A
    Haematologica; 2006 Dec; 91(12 Suppl):ECR57. PubMed ID: 17194663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
    Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
    Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
    Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
    Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
    [No Abstract]   [Full Text] [Related]  

  • 7. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
    Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
    Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
    Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
    Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.
    Flach J; Dicker F; Schnittger S; Kohlmann A; Haferlach T; Haferlach C
    Haematologica; 2010 Mar; 95(3):518-9. PubMed ID: 19903679
    [No Abstract]   [Full Text] [Related]  

  • 10. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
    Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
    Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
    [No Abstract]   [Full Text] [Related]  

  • 11. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
    Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
    Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
    Schnittger S; Bacher U; Haferlach C; Dengler R; Kröber A; Kern W; Haferlach T
    Leukemia; 2008 Feb; 22(2):453-5. PubMed ID: 17713548
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
    Huls G; Mulder AB; Rosati S; van de Loosdrecht AA; Vellenga E; de Wolf JT
    Blood; 2010 Jul; 116(2):180-2. PubMed ID: 20194893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
    Ziarkiewicz M; Dwilewicz-Trojaczek J; Pastwińska A; Chmarzyńska E; Paszkowska-Kowalewska M; Koperski Ł; Jędrzejczak WW; Ziarkiewicz-Wróblewska B
    Pol J Pathol; 2010; 61(2):105-9. PubMed ID: 20924996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
    Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
    Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
    [No Abstract]   [Full Text] [Related]  

  • 16. Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine.
    Kim J; Kim YR; Lee KA
    Leuk Lymphoma; 2012 Nov; 53(11):2287-9. PubMed ID: 22468921
    [No Abstract]   [Full Text] [Related]  

  • 17. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    Broséus J; Lippert E; Harutyunyan AS; Jeromin S; Zipperer E; Florensa L; Milosevic JD; Haferlach T; Germing U; Luño E; Schnittger S; Kralovics R; Girodon F
    Leukemia; 2014 Jun; 28(6):1374-6. PubMed ID: 24476766
    [No Abstract]   [Full Text] [Related]  

  • 18. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
    Jeromin S; Haferlach T; Grossmann V; Alpermann T; Kowarsch A; Haferlach C; Kern W; Schnittger S
    Haematologica; 2013 Feb; 98(2):e15-7. PubMed ID: 22929973
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T.
    Steensma DP; Tefferi A
    Blood; 2008 Feb; 111(3):1748. PubMed ID: 18223181
    [No Abstract]   [Full Text] [Related]  

  • 20. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
    Jeromin S; Haferlach T; Weissmann S; Meggendorfer M; Eder C; Nadarajah N; Alpermann T; Kohlmann A; Kern W; Haferlach C; Schnittger S
    Haematologica; 2015 Apr; 100(4):e125-7. PubMed ID: 25527566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.